Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alex Shimmings

Alexandra has more than 20 years' experience covering pharmaceutical and biotech R&D. An early interest in medicine, and a dawning realization that being a doctor was not for her, led to a degree in Biochemistry and Microbiology at the University of Leeds, and a move to London to pursue a career in medical journalism. Now Scrip's Managing Editor, Alex has held a variety of roles on the publication since starting as a science reporter in 1998. She instigated some of Scrip's signature features, such as the Pipeline Watch and New Active Substance lists, and also casts an editorial eye over the annual Scrip Awards. Alex's main work interests lie in novel drugs and pharmaceutical and biotech R&D, and she also enjoys medical history and current affairs.
Set Alert for Articles By Alex Shimmings

Latest From Alex Shimmings

Novartis Close To EU Approval For Zolgensma At Last

Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.

Approvals Companies

mRNA Vaccines – A Novel Weapon Against Coronavirus

The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.

Companies Coronavirus COVID-19

CureVac Denies Takeover Reports As It Slates Phase I Coronavirus Vaccine Study For Early Summer

The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.

Companies Coronavirus COVID-19

Lynparza/Recentin Combo Fails In Phase III PSR Ovarian Cancer

Lynparza will weather the failure of the Phase III GY004 study, but VEGF inhibitor Recentin’s future looks even less certain; other studies of the combination continue.

Clinical Trials Companies

Executives On The Move: Change At The Top For Endo And Santen, And Corporate Restructuring At Sanofi

Generics and specialty pharma Endo International and Japanese ophthalmic product company Santen Pharmaceutical each announce a new CEO. Meanwhile, restructuring at Sanofi results in departures of Chief Digital and Medical Officer, and EVPs of Primary Care, Business Transformation and External Affairs.

Appointments BioPharmaceutical

AstraZeneca Looks To FluMist Experience In COVID-19 Efforts

The UK firm speaks about its efforts to tackle the virus as a recent spike in COVID-19 cases outside China heighten concerns.

Companies Research & Development
See All
UsernamePublicRestriction

Register